-
Je něco špatně v tomto záznamu ?
Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use
Z. Papp, P. Agostoni, J. Alvarez, D. Bettex, S. Bouchez, D. Brito, V. Černý, J. Comin-Colet, MG. Crespo-Leiro, JF. Delgado, I. Édes, AA. Eremenko, D. Farmakis, F. Fedele, C. Fonseca, S. Fruhwald, M. Girardis, F. Guarracino, VP. Harjola, M....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, přehledy
- MeSH
- bezpečnost pacientů MeSH
- kardiotonika škodlivé účinky terapeutické užití MeSH
- kontrakce myokardu účinky léků MeSH
- lidé MeSH
- simendan škodlivé účinky terapeutické užití MeSH
- srdeční selhání diagnóza farmakoterapie mortalita patofyziologie MeSH
- vazodilatace účinky léků MeSH
- vazodilatancia škodlivé účinky terapeutické užití MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Levosimendan was first approved for clinical use in 2000, when authorization was granted by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely decompensated chronic heart failure (HF). In the ensuing 20 years, this distinctive inodilator, which enhances cardiac contractility through calcium sensitization and promotes vasodilatation through the opening of adenosine triphosphate-dependent potassium channels on vascular smooth muscle cells, has been approved in more than 60 jurisdictions, including most of the countries of the European Union and Latin America. Areas of clinical application have expanded considerably and now include cardiogenic shock, takotsubo cardiomyopathy, advanced HF, right ventricular failure, pulmonary hypertension, cardiac surgery, critical care, and emergency medicine. Levosimendan is currently in active clinical evaluation in the United States. Levosimendan in IV formulation is being used as a research tool in the exploration of a wide range of cardiac and noncardiac disease states. A levosimendan oral form is at present under evaluation in the management of amyotrophic lateral sclerosis. To mark the 20 years since the advent of levosimendan in clinical use, 51 experts from 23 European countries (Austria, Belgium, Croatia, Cyprus, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Italy, the Netherlands, Norway, Poland, Portugal, Russia, Slovenia, Spain, Sweden, Switzerland, the United Kingdom, and Ukraine) contributed to this essay, which evaluates one of the relatively few drugs to have been successfully introduced into the acute HF arena in recent times and charts a possible development trajectory for the next 20 years.
Anaesthesia and Intensive Care Division San Camillo Forlanini Hospital Rome Italy
Complexo Hospitalario Universitario A Coruña La Coruña Spain
Critical Care Proprietary Products Orion Pharma Espoo Finland
Department of Anaesthesiology and Intensive Care Medicine Medical University of Graz Graz Austria
Department of Anaesthesiology and Intensive Care Medicine University of Lübeck Lübeck Germany
Department of Anaesthesiology and Intensive Care Sahlgrenska University Hospital Gothenburg Sweden
Department of Anaesthesiology University Hospital Ghent Belgium
Department of Cardiology and Internal Medicine Nicolaus Copernicus University Torun Poland
Department of Cardiology Campus Virchow Klinikum Charité University Medicine Berlin Berlin Germany
Department of Cardiology Faculty of Medicine University of Debrecen Debrecen Hungary
Department of Cardiology Medical School University of Cyprus Nicosia Cyprus
Department of Cardiology Niguarda Ca'Granda Hospital Milan Italy
Department of Cardiology North Estonia Medical Centre Tallinn Estonia
Department of Cardiology Oslo University Hospital Ullevaal Oslo Norway
Department of Clinical Sciences and Community Health Centro Cardiologico Monzino IRCCS Milan Italy
Department of Intensive Care Hôpital Erasme Brussels Belgium
Department of Intensive Care Medicine Amsterdam UMC Amsterdam the Netherlands
Department of Medicine Spittal Limmattal Schlieren Switzerland
Departments of Cardiology and Transplantation Sahlgrenska University Hospital Gothenburg Sweden
Dipartimento di Anestesia e Terapie Intensive Azienda Ospedaliero Universitaria Pisana Pisa Italy
Emergency Medicine Meilahti Central University Hospital University of Helsinki Helsinki Finland
Global Medical Affairs R and D Orion Pharma Espoo Finland
Heart Diseases Institute Hospital Universitari de Bellvitge Barcelona Spain
Heart Failure Clinic São Francisco Xavier Hospital CHLO Lisbon Portugal
Institute of Anaesthesiology University Hospital of Zurich Zurich Switzerland
Institute of Medical Sciences Uppsala University Uppsala Sweden
Intensive Care Department Consorci Sanitari Integral University of Barcelona Barcelona Spain
Intensive Care Unit National Health Service Leeds United Kingdom
Klinik für Innere Medizin 3 Kardiologie Universitätsklinikum Schleswig Holstein Kiel Germany
Lomonosov Moscow State University Medical Centre Moscow Russia
Medizinische Klinik 2 Klinikum Weiden Teaching Hospital of University of Regensburg Weiden Germany
Statistical Services R and D Orion Pharma Espoo Finland
Struttura Complessa di Anestesia 1 Policlinico di Modena Modena Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21012424
- 003
- CZ-PrNML
- 005
- 20230131100908.0
- 007
- ta
- 008
- 210420s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/FJC.0000000000000859 $2 doi
- 035 __
- $a (PubMed)32639325
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Papp, Zoltán $u Department of Cardiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
- 245 10
- $a Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use / $c Z. Papp, P. Agostoni, J. Alvarez, D. Bettex, S. Bouchez, D. Brito, V. Černý, J. Comin-Colet, MG. Crespo-Leiro, JF. Delgado, I. Édes, AA. Eremenko, D. Farmakis, F. Fedele, C. Fonseca, S. Fruhwald, M. Girardis, F. Guarracino, VP. Harjola, M. Heringlake, A. Herpain, LMA. Heunks, T. Husebye, V. Ivancan, K. Karason, S. Kaul, M. Kivikko, J. Kubica, J. Masip, S. Matskeplishvili, A. Mebazaa, MS. Nieminen, F. Oliva, JG. Papp, J. Parissis, A. Parkhomenko, P. Põder, G. Pölzl, A. Reinecke, SE. Ricksten, H. Riha, A. Rudiger, T. Sarapohja, RHG. Schwinger, W. Toller, L. Tritapepe, C. Tschöpe, G. Wikström, DV. Lewinski, B. Vrtovec, P. Pollesello
- 520 9_
- $a Levosimendan was first approved for clinical use in 2000, when authorization was granted by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely decompensated chronic heart failure (HF). In the ensuing 20 years, this distinctive inodilator, which enhances cardiac contractility through calcium sensitization and promotes vasodilatation through the opening of adenosine triphosphate-dependent potassium channels on vascular smooth muscle cells, has been approved in more than 60 jurisdictions, including most of the countries of the European Union and Latin America. Areas of clinical application have expanded considerably and now include cardiogenic shock, takotsubo cardiomyopathy, advanced HF, right ventricular failure, pulmonary hypertension, cardiac surgery, critical care, and emergency medicine. Levosimendan is currently in active clinical evaluation in the United States. Levosimendan in IV formulation is being used as a research tool in the exploration of a wide range of cardiac and noncardiac disease states. A levosimendan oral form is at present under evaluation in the management of amyotrophic lateral sclerosis. To mark the 20 years since the advent of levosimendan in clinical use, 51 experts from 23 European countries (Austria, Belgium, Croatia, Cyprus, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Italy, the Netherlands, Norway, Poland, Portugal, Russia, Slovenia, Spain, Sweden, Switzerland, the United Kingdom, and Ukraine) contributed to this essay, which evaluates one of the relatively few drugs to have been successfully introduced into the acute HF arena in recent times and charts a possible development trajectory for the next 20 years.
- 650 _2
- $a kardiotonika $x škodlivé účinky $x terapeutické užití $7 D002316
- 650 _2
- $a srdeční selhání $x diagnóza $x farmakoterapie $x mortalita $x patofyziologie $7 D006333
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kontrakce myokardu $x účinky léků $7 D009200
- 650 _2
- $a bezpečnost pacientů $7 D061214
- 650 _2
- $a simendan $x škodlivé účinky $x terapeutické užití $7 D000077464
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a vazodilatace $x účinky léků $7 D014664
- 650 _2
- $a vazodilatancia $x škodlivé účinky $x terapeutické užití $7 D014665
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Agostoni, Piergiuseppe $u Department of Clinical Sciences and Community Health, Centro Cardiologico Monzino, IRCCS, Milan, Italy
- 700 1_
- $a Alvarez, Julian $u Department of Surgery, School of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain
- 700 1_
- $a Bettex, Dominique $u Institute of Anaesthesiology, University Hospital of Zurich, Zurich, Switzerland
- 700 1_
- $a Bouchez, Stefan $u Department of Anaesthesiology, University Hospital, Ghent, Belgium
- 700 1_
- $a Brito, Dulce $u Cardiology Department, Centro Hospitalar Universitario Lisboa Norte, CCUI, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
- 700 1_
- $a Černý, Vladimir $u Department of Anaesthesiology, Perioperative Medicine and Intensive Care, Masaryk Hospital, J.E. Purkinje University, Usti nad Labem, Czech Republic
- 700 1_
- $a Comin-Colet, Josep $u Heart Diseases Institute, Hospital Universitari de Bellvitge, Barcelona, Spain
- 700 1_
- $a Crespo-Leiro, Marisa G $u Complexo Hospitalario Universitario A Coruña (CHUAC), CIBERCV, Instituto de Investigacion Biomedica A Coruña (INIBIC), Universidad de a Coruña (UDC), La Coruña, Spain
- 700 1_
- $a Delgado, Juan F $u Heart Failure and Transplant Program, Cardiology Department, University Hospital 12 Octubre, Madrid, Spain
- 700 1_
- $a Édes, István $u Department of Cardiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
- 700 1_
- $a Eremenko, Alexander A $u Department of Cardiac Intensive Care, Petrovskii National Research Centre of Surgery, Sechenov University, Moscow, Russia
- 700 1_
- $a Farmakis, Dimitrios $u Department of Cardiology, Medical School, University of Cyprus, Nicosia, Cyprus $7 xx0281405
- 700 1_
- $a Fedele, Francesco $u Department of Cardiovascular, Respiratory, Nephrology, Anaesthesiology and Geriatric Sciences, La Sapienza University of Rome, Rome, Italy
- 700 1_
- $a Fonseca, Cândida $u Heart Failure Clinic, São Francisco Xavier Hospital, CHLO, Lisbon, Portugal
- 700 1_
- $a Fruhwald, Sonja $u Department of Anaesthesiology and Intensive Care Medicine, Division of Anaesthesiology for Cardiovascular Surgery and Intensive Care Medicine, Medical University of Graz, Graz, Austria
- 700 1_
- $a Girardis, Massimo $u Struttura Complessa di Anestesia 1, Policlinico di Modena, Modena, Italy
- 700 1_
- $a Guarracino, Fabio $u Dipartimento di Anestesia e Terapie Intensive, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
- 700 1_
- $a Harjola, Veli-Pekka $u Emergency Medicine, Meilahti Central University Hospital, University of Helsinki, Helsinki, Finland
- 700 1_
- $a Heringlake, Matthias $u Department of Anaesthesiology and Intensive Care Medicine, University of Lübeck, Lübeck, Germany
- 700 1_
- $a Herpain, Antoine $u Department of Intensive Care, Hôpital Erasme, Brussels, Belgium
- 700 1_
- $a Heunks, Leo M A $u Department of Intensive Care Medicine, Amsterdam UMC, Amsterdam, the Netherlands
- 700 1_
- $a Husebye, Tryggve $u Department of Cardiology, Oslo University Hospital Ullevaal, Oslo, Norway
- 700 1_
- $a Ivancan, Višnja $u Department of Anaesthesiology, Reanimatology and Intensive Care, University Hospital Centre, Zagreb, Croatia
- 700 1_
- $a Karason, Kristjan $u Departments of Cardiology and Transplantation, Sahlgrenska University Hospital, Gothenburg, Sweden
- 700 1_
- $a Kaul, Sundeep $u Intensive Care Unit, National Health Service, Leeds, United Kingdom
- 700 1_
- $a Kivikko, Matti $u Global Medical Affairs, R&D, Orion Pharma, Espoo, Finland
- 700 1_
- $a Kubica, Janek $u Department of Cardiology and Internal Medicine, Nicolaus Copernicus University, Torun, Poland
- 700 1_
- $a Masip, Josep $u Intensive Care Department, Consorci Sanitari Integral, University of Barcelona, Barcelona, Spain
- 700 1_
- $a Matskeplishvili, Simon $u Lomonosov Moscow State University Medical Centre, Moscow, Russia
- 700 1_
- $a Mebazaa, Alexandre $u Department of Anaesthesiology and Critical Care Medicine, AP-HP, Saint Louis and Lariboisière University Hospitals, Paris, France
- 700 1_
- $a Nieminen, Markku S $u Sydäntutkimussäätiö, Helsinki, Finland
- 700 1_
- $a Oliva, Fabrizio $u Department of Cardiology, Niguarda Ca'Granda Hospital, Milan, Italy
- 700 1_
- $a Papp, Julius G $u MTA-SZTE Research Group of Cardiovascular Pharmacology, Hungarian Academy of Sciences, University of Szeged, Szeged, Hungary
- 700 1_
- $a Parissis, John $u Second Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece
- 700 1_
- $a Parkhomenko, Alexander $u Emergency Cardiology Department, National Scientific Centre MD Strazhesko Institute of Cardiology, Kiev, Ukraine
- 700 1_
- $a Põder, Pentti $u Department of Cardiology, North Estonia Medical Centre, Tallinn, Estonia
- 700 1_
- $a Pölzl, Gerhard $u Department of Internal Medicine III, Cardiology and Angiology, Medical University of Innsbruck, Innsbruck, Austria
- 700 1_
- $a Reinecke, Alexander $u Klinik für Innere Medizin III, Kardiologie, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
- 700 1_
- $a Ricksten, Sven-Erik $u Department of Anaesthesiology and Intensive Care, Sahlgrenska University Hospital, Gothenburg, Sweden
- 700 1_
- $a Riha, Hynek $u Department of Anaesthesiology and Intensive Care Medicine, Cardiothoracic Anaesthesiology and Intensive Care, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Rudiger, Alain $u Department of Medicine, Spittal Limmattal, Schlieren, Switzerland
- 700 1_
- $a Sarapohja, Toni $u Statistical Services, R&D, Orion Pharma, Espoo, Finland
- 700 1_
- $a Schwinger, Robert H G $u Medizinische Klinik II, Klinikum Weiden, Teaching Hospital of University of Regensburg, Weiden, Germany
- 700 1_
- $a Toller, Wolfgang $u Department of Anaesthesiology and Intensive Care Medicine, Medical University of Graz, Graz, Austria
- 700 1_
- $a Tritapepe, Luigi $u Anaesthesia and Intensive Care Division, San Camillo-Forlanini Hospital, Rome, Italy
- 700 1_
- $a Tschöpe, Carsten $u Department of Cardiology, Campus Virchow Klinikum, Charité-University Medicine Berlin, Berlin, Germany
- 700 1_
- $a Wikström, Gerhard $u Institute of Medical Sciences, Uppsala University, Uppsala, Sweden
- 700 1_
- $a Lewinski, Dirk von $u Department of Cardiology, Myokardiale Energetik und Metabolismus Research Unit, Medical University of Graz, Graz, Austria
- 700 1_
- $a Vrtovec, Bojan $u Department of Cardiology, Advanced Heart Failure and Transplantation Centre, University Clinical Centre, Ljubljana, Slovenia
- 700 1_
- $a Pollesello, Piero $u Critical Care Proprietary Products, Orion Pharma, Espoo, Finland
- 773 0_
- $w MED00002571 $t Journal of cardiovascular pharmacology $x 1533-4023 $g Roč. 76, č. 1 (2020), s. 4-22
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32639325 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210420 $b ABA008
- 991 __
- $a 20230131100904 $b ABA008
- 999 __
- $a ok $b bmc $g 1650737 $s 1132803
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 76 $c 1 $d 4-22 $e - $i 1533-4023 $m Journal of cardiovascular pharmacology $n J Cardiovasc Pharmacol $x MED00002571
- LZP __
- $a Pubmed-20210420
